Research programme: allergy therapy - Infinity Pharmaceuticals/Kyorin

Drug Profile

Research programme: allergy therapy - Infinity Pharmaceuticals/Kyorin

Alternative Names: Allergy therapy research programme - Infinity Pharmaceuticals/Kyorin

Latest Information Update: 07 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Infinity Pharmaceuticals; Kyorin Pharmaceutical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypersensitivity

Most Recent Events

  • 26 Sep 2006 No development reported - Preclinical for Allergy in USA (unspecified route)
  • 13 Sep 2006 Discovery Partners International has been acquired and merged into Infinity Pharmaceuticals
  • 09 Sep 2003 Preclinical trials in Allergy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top